Overview

Study to Assess Sarilumab in Halting Progression of Morphea

Status:
Withdrawn
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Regeneron Pharmaceuticals